Kaoru Tsuchiya

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng et al. · The Lancet · 2023 · 415 citations · Full text

Surgical Oncology, Hepatology, Medicine +8

Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection†

Yasuhiro Asahina, Kaoru Tsuchiya, Nobuharu Tamaki et al. · Hepatology · 2010 · 296 citations · Full text

α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C

Yasuhiro Asahina, Kaoru Tsuchiya, Takashi Nishimura et al. · Hepatology · 2013 · 247 citations · Full text

Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH‐HCC Guidelines)

Kiyoshi Hasegawa, Nobuyuki Takemura, Tatsuya Yamashita et al. · Hepatology Research · 2023 · 235 citations · Full text

Pathology, Cancer Registration, Clinical Practice Guidelines +18

FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma

Tokuzo Arao, Kazuomi Ueshima, Tomoyuki Nagai et al. · Hepatology · 2012 · 152 citations · Full text